Mean difference for cilazapril and captopril versus placebo (12–0 weeks) and cilazapril (24–12 weeks), compared with the group that continued with cilazapril
| Dimension | Cilazapril v placebo | Captopril v placebo | Cilazapril (starting v continuing) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12–0 weeks | 12–0 weeks | 24–12 weeks | |||||||||
| Difference (SD) | 95% CI | Effect size | Difference (SD) | 95% CI | Effect size | Difference (SD) | 95% CI | Effect size | |||
| SIP | |||||||||||
| Ambulation | +1.33 (9.1) | −1.04, 3.70 | 0.15 | +1.57 (9.3) | −1.23, 4.37 | 0.17 | +0.05 (6.8) | −1.79, 1.89 | 0.01 | ||
| Mobility | +2.07 (11.2) | −0.86, 5.00 | 0.18 | +1.67 (10.8) | −1.59, 4.93 | 0.15 | +1.30 (6.7) | −0.53, 3.13 | 0.19 | ||
| Body care and movement | −0.01 (6.0) | −1.57, 1.55 | 0.00 | +0.29 (6.2) | −1.58, 2.16 | 0.05 | +1.12 (4.5) | −0.11, 2.35 | 0.25 | ||
| Physical dimension | +0.73 (6.1) | −0.86, 2.32 | 0.12 | +0.87 (6.1) | −0.96, 2.70 | 0.14 | +0.90 (4.3) | −0.26, 2.06 | 0.21 | ||
| Psychosocial dimension | −0.62 (8.4) | −2.81, 1.57 | –0.07 | −0.10 (9.1) | −2.84, 2.64 | –0.01 | +1.46 (5.6) | −0.05, 2.97 | 0.26 | ||
| Total SIP | −0.08 (6.3) | −1.71, 1.55 | –0.01 | +0.56 (6.5) | −1.41, 2.53 | 0.09 | +0.88 (4.2) | −0.25, 2.01 | 0.21 | ||
| Total POMS | +1.90 (19.9) | −3.81, 7.61 | 0.10 | +3.78 (22.8) | −3.78, 11.34 | 0.17 | +3.86 (17.2) | −1.21, 8.93 | 0.22 | ||
| HSI | +0.02 (0.13) | −0.01, 0.05 | 0.16 | +0.02 (0.14) | −0.02, 0.06 | 0.15 | +0.02 (0.12) | −0.01, 0.05 | 0.17 | ||
A positive result is an improvement with active drug; 95% CI for the difference and effect size.
SIP, sickness impact dimensions; POMS, total profile of mood states; HSI, health status index.